This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluatethe efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel(standard of care) in participants with programmed death ligand 1 (PD-L1)-positivemetastatic non-small cell lung cancer (NSCLC) who have been treated with programmed celldeath protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administeredeither in combination or sequentially in the metastatic setting.
This is a multicenter, randomized, open-label, international, Phase 3 trial to evaluatethe efficacy and safety of acasunlimab in combination with pembrolizumab versus docetaxel(standard of care) in participants with programmed death ligand 1 (PD-L1)-positivemetastatic non-small cell lung cancer (NSCLC) who have been treated with programmed celldeath protein 1 (PD-1)/PD-L1 inhibitor and platinum-containing chemotherapy, administeredeither in combination or sequentially in the metastatic setting.
